|
|
|
|
|
|
|
|
|
|
"Vintafolide and etarfolatide are currently being evaluated in a Phase 3 randomized, double-blind clinical trial for platinum-resistant ovarian cancer (PROCEED trial; ClinicalTrials.gov Identifier NCT01170650)"
Saturday, March 02, 2013
financial news: Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer and Non-Small Cell Lung Cancer Patients Most Likely to Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows
"Vintafolide and etarfolatide are currently being evaluated in a Phase 3 randomized, double-blind clinical trial for platinum-resistant ovarian cancer (PROCEED trial; ClinicalTrials.gov Identifier NCT01170650)"
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.